Siemens Fonds Invest GmbH Reduces Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Posted by on Jun 13th, 2023

Siemens Fonds Invest GmbH cut its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 9.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 909 shares of the medical instruments supplier’s stock after selling 97 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in West Pharmaceutical Services were worth $214,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of West Pharmaceutical Services by 1.1% during the third quarter. Vanguard Group Inc. now owns 8,925,965 shares of the medical instruments supplier’s stock worth $2,196,501,000 after purchasing an additional 92,870 shares during the period. BlackRock Inc. lifted its holdings in shares of West Pharmaceutical Services by 0.4% during the third quarter. BlackRock Inc. now owns 8,090,611 shares of the medical instruments supplier’s stock worth $1,990,938,000 after purchasing an additional 34,875 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of West Pharmaceutical Services by 40.5% during the third quarter. Bank of New York Mellon Corp now owns 1,742,487 shares of the medical instruments supplier’s stock worth $428,787,000 after purchasing an additional 502,186 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of West Pharmaceutical Services by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 1,506,824 shares of the medical instruments supplier’s stock worth $353,983,000 after purchasing an additional 36,935 shares during the last quarter. Finally, Brown Advisory Inc. raised its holdings in shares of West Pharmaceutical Services by 24.1% during the third quarter. Brown Advisory Inc. now owns 1,216,793 shares of the medical instruments supplier’s stock worth $299,428,000 after purchasing an additional 236,270 shares during the last quarter. 91.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on WST shares. KeyCorp raised their target price on shares of West Pharmaceutical Services from $315.00 to $375.00 and gave the stock an “overweight” rating in a report on Friday, February 17th. Stephens raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $330.00 to $400.00 in a report on Tuesday, April 11th. Deutsche Bank Aktiengesellschaft raised their target price on West Pharmaceutical Services from $250.00 to $290.00 in a report on Wednesday, February 22nd. Finally, StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Tuesday. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, West Pharmaceutical Services has an average rating of “Hold” and an average price target of $313.00.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,000 shares of the stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $343.05, for a total transaction of $343,050.00. Following the completion of the transaction, the vice president now owns 1,829 shares of the company’s stock, valued at $627,438.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Eric Mark Green sold 44,000 shares of the company’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $363.10, for a total transaction of $15,976,400.00. Following the completion of the sale, the chief executive officer now owns 134,574 shares of the company’s stock, valued at $48,863,819.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Charles Witherspoon sold 1,000 shares of the company’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $343.05, for a total transaction of $343,050.00. Following the sale, the vice president now directly owns 1,829 shares of the company’s stock, valued at approximately $627,438.45. The disclosure for this sale can be found here. Insiders sold 67,244 shares of company stock valued at $24,454,553 over the last quarter. 1.13% of the stock is currently owned by insiders.

West Pharmaceutical Services Stock Up 2.6 %

Shares of WST opened at $357.39 on Tuesday. The company has a current ratio of 3.62, a quick ratio of 2.79 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $206.19 and a 12 month high of $376.72. The stock’s 50 day moving average is $354.43 and its two-hundred day moving average is $303.54. The firm has a market cap of $26.53 billion, a P/E ratio of 49.09, a PEG ratio of 7.18 and a beta of 1.10.

West Pharmaceutical Services (NYSE:WST – Get Rating) last posted its quarterly earnings data on Thursday, April 27th. The medical instruments supplier reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.31. The business had revenue of $716.60 million for the quarter, compared to the consensus estimate of $697.28 million. West Pharmaceutical Services had a net margin of 19.15% and a return on equity of 24.14%. The company’s revenue was down .5% compared to the same quarter last year. During the same period last year, the firm posted $2.30 earnings per share. Analysts predict that West Pharmaceutical Services, Inc. will post 7.68 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 2nd. Shareholders of record on Wednesday, July 26th will be issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.21%. The ex-dividend date of this dividend is Tuesday, July 25th. West Pharmaceutical Services’s payout ratio is 10.44%.

West Pharmaceutical Services Company Profile

(Get Rating)

West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.

Featured Stories

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.